Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Core Insights - Sionna Therapeutics is advancing its clinical pipeline for cystic fibrosis (CF) with ongoing trials for NBD1 stabilizers SION-719 and SION-451, with topline data expected in mid-2026 [1][2] Pipeline Updates - The PreciSION CF Phase 2a proof-of-concept trial for SION-719 is evaluating its safety and efficacy as an add-on to standard care in CF patients, with topline data anticipated in mid-2026 [1][4] - The Phase 1 trial for SION-451, in combination with SION-2222 and SION-109, is also on track, with topline data expected in mid-2026 [1][4] - Data presented at the 2025 North American Cystic Fibrosis Conference showed that both SION-719 and SION-451 were well tolerated and increased the half-life of F508del-CFTR protein to levels seen in wild-type [4] Financial Performance - Research and development expenses for Q4 2025 were $15.2 million, up from $14.3 million in Q4 2024, and for the full year, they totaled $60.3 million compared to $57.3 million in 2024 [3] - General and administrative expenses for Q4 2025 were $8.4 million, compared to $3.9 million in Q4 2024, and for the full year, they were $28.7 million versus $13.3 million in 2024 [4] - The net loss for Q4 2025 was $20.4 million, compared to a net loss of $15.8 million in Q4 2024, and for the full year, the net loss was $75.3 million compared to $61.7 million in 2024 [5] Cash Position - As of December 31, 2025, Sionna had approximately $310.3 million in cash and cash equivalents, which is expected to fund operations into 2028 [6][11]